Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
Mayo Clinic
AstraZeneca
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
ViroMissile, Inc.
Seagen Inc.
Essen Biotech
OHSU Knight Cancer Institute
DualityBio Inc.
MacroGenics
City of Hope Medical Center
Jiangsu Simcere Pharmaceutical Co., Ltd.
Wondercel Biotech (ShenZhen)
ImmunityBio, Inc.
Indaptus Therapeutics, Inc
Ocellaris Pharma, Inc.
Mayo Clinic
Incyte Corporation
Mayo Clinic
GV20 Therapeutics
NeoTX Therapeutics Ltd.
West China Hospital
DualityBio Inc.
Sotio Biotech Inc.
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
Coherus Oncology, Inc.
University of Pittsburgh
BioInvent International AB
7 Hills Pharma, LLC
Pfizer
GONGCHU Biotechnology Co., Ltd
Exelixis
Incyte Corporation
Jonsson Comprehensive Cancer Center
Cancer Research UK
University of Virginia
Incyte Corporation
Incyte Corporation
University Hospital, Angers
Telix Pharmaceuticals (Innovations) Pty Limited
Shanghai Public Health Clinical Center
City of Hope Medical Center
3D Medicines
HC Biopharma Inc.
Regeneron Pharmaceuticals
Bristol-Myers Squibb